A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2024-12-10
Target enrollment:
Participant gender:
Summary
A open-label, single-arm, phase II trial to study was designed to evaluate the effectiveness
and safety of trastuzumab and pyrotinib in treating HER2 positive patients who have
previously treated, locally advanced, or metastatic urothelial carcinoma.